Earnings Forecast Research on Illumina, Inc. (ILMN)

Illumina, Inc. has received $0.81 as the consensus Earnings Estimate for the Quarter ending on Dec 2016 ,According to the estimate provided by 12 Financial Advisor in the Stock Trading Firms. Among 12 Analysts, Bottom line EPS Estimate for the current quarter is $0.75 while the top line estimate is $0.88 , a key information to consider for Day Trading and investing in stocks. The EPS growth rate is projected at -0.21%.

Illumina, Inc. reported better than expected with a surprise EPS of 11.49% or $0.1 during its most recent quarterly earnings. The Actual EPS was $0.97 compared to the Estimated EPS of $0.87. San Diego based Illumina, Inc. Last reported the Quarter results on Dec 31, 2016 and the Next earnings date is scheduled to be released on Jan 31, 2017.

Illumina, Inc. has a Price to Earnings ratio of 47.55 for the trailing twelve month period. The price to book ratio of the company for the most recent quarter is 10.07. For the Most Recent Fiscal Year, Illumina, Inc. has a price to cash ratio of 35.32. For the Trailing twelve month period, company showed a Net Profit Margin of 18.72% and Return on Equity of the stock is 23.76%.

In the last quarter, Illumina, Inc. reported Annual Earnings of $0.97. Based on the filings, last years Annual Earnings was, $3.32. In the last Quarter, ILMN reported a surprise Earnings per Share of 11.49% . The consensus estimate for current quarter is $0.81 and for the current fiscal year, the estimate is $3.34. For the Next fiscal year, the estimate is $3.67 based on the consensus.

Illumina, Inc. (NASDAQ:ILMN) : On Tuesday heightened volatility was witnessed in Illumina, Inc. (NASDAQ:ILMN) which led to swings in the share price. The stock opened for trading at $159.28 and hit $160.6 on the upside , eventually ending the session at $160.1, with a gain of 0.51% or 0.82 points. The heightened volatility saw the trading volume jump to 1,743,442 shares. The 52-week high of the share price is $186.88 and the company has a market cap of $23,519 million. The 52-week low of the share price is at $119.37 .

Illumina Inc. is a leading developer of next-generation tools for the large-scale analysis of genetic variation and function. The companys tools will provide information that could be used to improve drugs and therapies, customize diagnoses and treatment, and cure disease. The company is developing a comprehensive line of products that can address the scale of experimentation and the breadth of functional analysis required to achieve the goals of molecular medicine.


Share this post

Leave a Reply